CF Foundation's $3.3bn royalty sale will fund drugs, services

The Cystic Fibrosis Foundation's (CFF) $150m investment in therapies developed by Vertex Pharmaceuticals, including Kalydeco (ivacaftor), paid off in a big way: the nonprofit patient advocacy group sold its future royalties from the cystic fibrosis (CF) medicines to Royalty Pharma for $3.3bn.

The Cystic Fibrosis Foundation's (CFF) $150m investment in therapies developed by Vertex Pharmaceuticals, including Kalydeco (ivacaftor), paid off in a big way: the nonprofit patient advocacy group sold its future royalties from the cystic fibrosis (CF) medicines to Royalty Pharma for $3.3bn.

CFF still is deciding exactly how it will spend the cash and over how long a period, but CF patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category